Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13 (4), 342-8

Global Economic Burden of Chagas Disease: A Computational Simulation Model

Affiliations

Global Economic Burden of Chagas Disease: A Computational Simulation Model

Bruce Y Lee et al. Lancet Infect Dis.

Abstract

Background: As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers. We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective.

Methods: Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death. Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports. We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions. We used a discount rate of 3% to adjust all costs and DALYs to present-day values.

Findings: On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually. Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs. Globally, the annual burden is $627·46 million in health-care costs and 806,170 DALYs. The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29,385,250 DALYs. Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27,684. Global costs are $7·19 billion per year and $188·80 billion per lifetime. More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic. A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality.

Interpretation: The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease.

Funding: Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.

Conflict of interest statement

Conflicts of interest

We declare that we have no conflicts of interest.

Figures

Figure 1
Figure 1. Individual-based Chagas disease model structure
Generated per-person disease cost and disability-adjusted life-year estimates. p=probability. CHF=congestive heart failure. *For annual burden estimates, all individuals began model in this state. †Individuals who survived acute disease transitioned to the indeterminate disease state. ‡pIndeterminate=1−pAcute.
Figure 2
Figure 2. Effect of varying model parameters on the annual health-care cost per case of Chagas disease
Chagas disease endemicity had no effect on the cost of a case. GDP=gross domestic product. *±1% for surgeries.

Comment in

Similar articles

  • Cost of depression in Europe.
    Sobocki P, Jönsson B, Angst J, Rehnberg C. Sobocki P, et al. J Ment Health Policy Econ. 2006 Jun;9(2):87-98. J Ment Health Policy Econ. 2006. PMID: 17007486
  • The Global Economic and Health Burden of Human Hookworm Infection.
    Bartsch SM, Hotez PJ, Asti L, Zapf KM, Bottazzi ME, Diemert DJ, Lee BY. Bartsch SM, et al. PLoS Negl Trop Dis. 2016 Sep 8;10(9):e0004922. doi: 10.1371/journal.pntd.0004922. eCollection 2016 Sep. PLoS Negl Trop Dis. 2016. PMID: 27607360 Free PMC article.
  • Cost of disorders of the brain in Europe 2010.
    Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group. Gustavsson A, et al. Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Eur Neuropsychopharmacol. 2011. PMID: 21924589
  • Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
    Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T. Whiteford HA, et al. Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993280 Review.
  • Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.
    Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJ, Vos T. Degenhardt L, et al. Lancet. 2013 Nov 9;382(9904):1564-74. doi: 10.1016/S0140-6736(13)61530-5. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993281 Review.
See all similar articles

Cited by 142 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback